Abstract

The development of sodium-glucose transporter 2 inhibitor (SGLT2i) broadens the therapeutic strategies in treating diabetes mellitus. By inhibiting sodium and glucose reabsorption from the proximal tubules, the improvement in insulin resistance and natriuresis improved the cardiovascular mortality in diabetes mellitus (DM) patients. It has been known that SGLT2i also provided renoprotection by lowering the intraglomerular hypertension by modulating the pre- and post- glomerular vascular tone. The application of SGLT2i also provided metabolic and hemodynamic benefits in molecular aspects. The recent DAPA-CKD trial and EMPEROR-Reduced trial provided clinical evidence of renal and cardiac protection, even in non-DM patients. Therefore, the aim of the review is to clarify the hemodynamic and metabolic modulation of SGLT2i from the molecular mechanism.

Highlights

  • Sodium–glucose cotransporter (SGLT) 2 inhibitors (SGLT2i) are essential in the therapeutic management of diabetic nephropathy

  • This study reviews the pleiotropic effect of sodium-glucose transporter 2 inhibitor (SGLT2i), in the management of cardiorenal syndrome based on molecular mechanisms

  • Clinical trials have failed to demonstrate the use of SGLT2i compensatory heart rate (HR) increase [53]. These findings suggest a sympatholytic effect of SGLT2i, which may contribute to the cardioprotective effects of SGLT2i treatment

Read more

Summary

Introduction

Sodium–glucose cotransporter (SGLT) 2 inhibitors (SGLT2i) are essential in the therapeutic management of diabetic nephropathy. Their role in lowering the mortality associated with congestive heart failure and in alleviating the glomerular filtration rate (GFR) decline has been proven by multiple landmark clinical trials. They improve mortality by reducing the sodium and glucose load on the body. This study reviews the pleiotropic effect of SGLT2i, in the management of cardiorenal syndrome based on molecular mechanisms

Mechanism of Glomerular Hyperfiltration in Diabetes
Hemodynamic Factors Affected by SGLT2i
Renal Hemodynamic Effects of SGLT2i in Patients with T1DM
Effects on Intrarenal RAS
Ameliorate the Chronic Activation of the Sympathetic Nervous System
SGLT2i Reduces SNS Activity
Effects of SGLT2i on Insulin Sensitivity and β-Cell Function
Effects of SGLT2 Inhibition on Kidney Pathological Findings
SGLT2i Contributes to Cardiac and Renal Metabolism
Anti-Inflammatory Effects of SGLT2i
SGLT2i Reduces Renal Fibrosis and Enhances EPO Production
SGLT2i in Acute Kidney Injury
4.10. Effects of SGLT2i on Bone Metabolism
4.11. SGLT2i on Non-Osmotic Sodium Storage and Interstitial Fluid Dynamics
4.12. Uremic Toxin-Lowering Effect of Relative Nonspecific SGLT2i
The Protection of SGLT2i in Cardiac and Kidney Outcomes
Findings
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call